Sionna Therapeutics, Inc. Investigation - SION

Company
Sionna Therapeutics, Inc. (NASDAQ: SION)

Learn more about the Sionna Therapeutics, Inc. Investigation

Required Field

Required Field

Required Field

  • $1 - $1,000
  • $1001 - $10,000
  • $10,001 - $25,000
  • $25,001 - $50,000
  • $50,001 - $100,000
  • $100,001 - $250,000
  • $250,001 - $500,000
  • $500,000+

There is no cost or obligation for you to submit.

The submission of this form does not create an attorney-client relationship.

Please Upload related files below

Add Transactions

Purchases

1.
  • Common Stock
  • Preferred Stock
  • Bonds
  • Calls
  • Puts
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12

Additional Purchases

Sales

1.
  • Common Stock
  • Preferred Stock
  • Bonds
  • Calls
  • Puts
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12

Additional Sales

Please input at least 1 transaction or press "skip for now" button below

Please fill in all the fields for your transaction or press "skip for now" button below

Alternatively, you may upload your transactions below or e-mail them to [email protected]

Upload Your Stock Tickers

Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.

Don’t miss out on possible monetary recovery - link your brokerage account with SnapTrade.

Skip

Sionna Therapeutics, Inc. Investigation Details

Sionna Therapeutics shares collapsed approximately 92% after the Company disclosed that its Phase 2a PreciSION CF trial of SION-719 failed to achieve its key activity endpoint and that it would not advance the candidate as an add-on therapy. According to the Company's disclosure, SION-719 -- administered on top of standard of care -- produced a placebo-adjusted sweat chloride change of -1.0 mmol/L, with a p-value of 0.7. Sionna stated it would not advance SION-719 as an add-on therapy. The decline did not follow an apparent liquidity shortfall: Sionna reported approximately $268.3 million in cash, cash equivalents and marketable securities as of June 30, 2026, and a second-quarter net loss of $29.9 million. Sionna's NBD1 stabilizer programs are central to its cystic fibrosis pipeline. The Company's FY2025 Form 10-K stated that it was "substantially dependent on the success of at least one of our nucleotide binding domain 1 ('NBD1') stabilizers." The investigation concerns whether SION investors received adequate disclosure regarding the Company’s reliance on its NBD1 stabilizer programs and the risks associated with the SION-719 program.

Get Started